Sensus Healthcare近日发布2025年第四季度财务报告，其中特别值得关注的是针对非黑色素瘤皮肤癌的浅表放射治疗（SRT）技术已获得专属CPT编码的正式公布。这一里程碑事件标志着该治疗方案在医疗报销体系中获得重要突破，为医疗机构采用该技术提供了明确的收费依据。
财报数据显示，公司在第四季度展现出稳健的财务表现。专属CPT编码的发布将进一步提升Sensus Healthcare的SRT设备在皮肤癌治疗领域的市场竞争力，为患者提供更精准、更便捷的治疗选择。这一进展预计将对公司未来业绩产生积极影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.